The FDA has issued a new draft guidance to direct medical device manufacturers on how to ensure power morcellator tissue containment systems are safe and will not put women at…
The CDC is considering a review of how gynecologists evaluate women for hidden uterine cancer and other sarcomas, which may result in new guidelines.
European regulators are raising concerns that the uterine fibroid drug Esmya, awaiting approval in the U.S., may be linked to liver damage and liver failure risks.
The FDA reports that risks of contracting uterine cancer from power morcellation could be as high as 1-in-225, and also warns that cancer spread through morcellation appears to be more…
A new editorial say failures to more quickly identify and react to power morcellator cancer risk were in part due to a lack of a sound post-marketing surveillance system to…
A long-ignored technique known as embolization may be an under-used means of uterine fibroid removal, according to a new study. which comes as the medical community abandons morcellation procedures due…
A GAO report indicates that the FDA's adverse reporting system and its voluntary nature may have delayed the agency from detecting heightened cancer risks linked to the use of power…
Olympus has received approval for a new morcellator equipped with a tissue containment bag, amid concerns that morcellators can spread cancerous cells throughout a woman's body.
Researchers have seen no increase in hysterectomy complications as the medical community walks back from power morcellator use over cancer fears, according to a new study.
A bill proposed last week would make reporting adverse medical device events mandatory in the face of concerns over morcellators and the Essure birth control implant.